TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00777504

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usage oral angiogenesis inhibitor
Description: see under 'study arms'

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stop oral angiogenesis inhibitor
Description: see under 'study arms'
Study: NCT03263052

Intervention type: DRUG
Intervention: Tacrolimus XR (Envarsus)
Description: Elderly patients (age 60 or older) on tacrolimus experiencing neurological AEs (tremor, insomnia, vertigo, photophobia, mood disturbances, or headache) presumably from tacrolimus immediate-release or tacrolimus XL will be converted to Envarsus. This conversion will be based on the Envarsus package insert which is a 20% reduction in total daily dose and is taken once a day. The conversion from Astagraf to Envarsus will be a 36% reduction.
Study: NCT02087020

Intervention type: PROCEDURE
Intervention: Debridement, antibiotics and implant retention
Description: DAIR treatment protocol embodies an extensive surgical debridement and a radical excision of infected tissue. This is followed by exchange of modular components (articulating surfaces of the implant such as the femoral head, acetabular liner in total hip arthroplasty and the tibial insert, the polyethylene meniscus, in total knee arthroplasty). The wound is then copiously irrigated (\> 9 litre) with 0.9 % sodium chloride and then closed.
Study: NCT03836014

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Daratumumab/Lenalidomide/Dexamethasone for 24 months
Description: Conditioning regimen: 16 mg/kg IV :~* Weekly (Cycles 1 and C2)~* Every two weeks (C3 to C6)~* Monthly from C7 up to 24 months in total (Arm 1)~Infusion reaction prophylaxis :~* Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~* An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~* Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle up to 24 months in total (Arm 1)~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle up to 24 months in total (Arm 1)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab/Lenalidomide/Dexamethasone until progression
Description: Conditioning regimen: 16 mg/kg IV :~* Weekly (Cycles 1 and C2)~* Every two weeks (C3 to C6)~* Monthly from C7 until disease progression (Arm 2).~Infusion reaction prophylaxis :~* Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~* An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~* Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle until disease progression (Arm 2).~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle until disease progression (Arm 2).
Study: NCT01491152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galileo® tilt table for children
Description: Two weeks of introduction and 12 weeks of training with side-alternating whole body vibration (WBV) (Galileo® tilt table)
Study: NCT03009734

Intervention type: DRUG
Group type: OTHER
Intervention: ATx201 dermal formulations 2%
Description: Topical application of ATx201 dermal formulations 2%
Study: NCT01966029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 110
Description: All pateints receive treatment with BMN 110
Study: NCT04105465

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PlasmaJet
Description: The PlasmaJet device is used following groin node dissection on the side randomised to receive it as per protocol specifications
Study: NCT01851824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acenocoumarol
Description: 4 mg single oral doses on Days 1 and 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg orally bid, 20 days (Days 4-23)
Study: NCT00453076

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel eluting covered metal stent and control covered metal stent
Description: Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting covered metal stent and control covered metal stent
Description: Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique
Study: NCT04118049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) and RestoreTM gel.
Description: BiopHreshTM is a vaginal probiotic supplement that is offered over the counter and contains four different lactobacilli strains (L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus). RestoreTM is a moisturizing personal lubricant that has been on the market for three years. Participants will use 1 probiotic capsule with RestoreTM gel nightly three times weekly.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard care arm is standard care for pessary use. Pessary maintenance will be performed standardly by their provider.
Study: NCT01669291

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antagonist
Description: Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.
Study: NCT01868906

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-FMISO
Description: 18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.
Study: NCT01843062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: 3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
Study: NCT01868906

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-FMISO
Description: 18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET without SCS
Description: PET-scanning using 18F-fluoromisonidazole without SCS
Study: NCT01843062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Radioactive Iodine Therapy
Description: A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioactive Iodine Therapy
Description: A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
Study: NCT01970267

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Ablation of Floaters

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Treatment
Description: Laser will be set at 0.3 millijoules (mJ). There will be a 100% absorptive filter (black spot) of about 1cm placed centrally on the lens. All laser aiming beams will be placed within the 1cm filter. Laser will be applied at 0.3 mJ at the absorptive black spot (100% density filter) in order to create a realistic treatment therapy procedure.
Study: NCT01598922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Cognitive Behavioral Therapy
Description: 8 weeks of online treatment program
Study: NCT01781130

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Steroid injection
Study: NCT04284176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy and action-observation therapy
Description: The mirror therapy and action-observation therapy group will receive for 20 days a daily therapy of 15 minutes at home of MT and 45 of AOT, whereas the action-observation therapy group will receive 60 minutes of AOT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy and action-observation therapy
Description: The mirror therapy and action-observation therapy group will receive for 20 days a daily therapy of 15 minutes at home of MT and 45 of AOT, whereas the action-observation therapy group will receive 60 minutes of AOT.
Study: NCT02386449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium picosulfate, magnesium oxide and citric acid (Picoprep®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mannitol
Study: NCT01963910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% Mannitol in vehicle cream
Description: applied to one half of the upper lip following removal of capsaicin cream.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle cream
Description: application to the other half of the upper lip following capsaicin cream removal
Study: NCT01868906

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET without SCS
Description: PET-scanning using 18F-fluoromisonidazole without SCS

Intervention type: DEVICE
Group type: OTHER
Intervention: SCS
Description: Electrical stimulation of spinal cord, minimally invasive neurosurgical technique used to treat refractory pain and ischemic syndromes.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET without/with SCS
Description: Second PET-scanning using 18F-fluoromisonidazole: without/with SCS

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Standard radiation therapy

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Standard radiation therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Standard treatment with concurrent and adjuvant Temozolomide.

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Standard treatment with concurrent and adjuvant Temozolomide.
Study: NCT04540653

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Standard vaccination schedule
Description: Administer a standard vaccination schedule (three doses of 20 μg of the hepatitis B vaccine, in months 0, 1, 6) at an age of ≥50 years and evaluate a production kinetics after each dose administered in the period of about 30 to 60 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reinforced vaccination schedule
Description: Administer an enhanced vaccination schedule (three doses of 40 μg of the hepatitis B vaccine, in months 0, 1, 6) in individuals aged ≥50 years and assess the kinetics of antibody production after each dose administered in the period of approximately 30 to 60 days.
Study: NCT02386449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl
Study: NCT06315946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pixie® skin tag
Description: The skin tag is treated by treatment with the cryogenic device. To protect the surrounding skin, a protective foam plaster is applied before the device is used on the skin tag. The skin tag is treated for 20 seconds after loading the device for 2 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wortie® Skin Tag Remover
Description: The skin tag is treated by treatment with the cryogenic device. The frozen metal nib is applied on the skin tag for 40 seconds.
Study: NCT04906304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus Pill
Description: standard dose versus low dose Sandimun
Study: NCT03857165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAP-001
Description: SAP-001 or placebo treatment in a 3:1 randomization ratio.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAP-001
Description: SAP-001 or placebo treatment in a 3:1 randomization ratio.
Study: NCT04906304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus Pill
Description: standard dose versus low dose Sandimun
Study: NCT03857165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAP-001
Description: SAP-001 or placebo treatment in a 3:1 randomization ratio.
Study: NCT03568136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Description: Solution for injection in pre-filled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab 300 mg
Description: Solution for injection in pre-filled syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for injection in pre-filled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection in pre-filled syringe
Study: NCT00920582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Teplizumab Herold Regimen
Description: Full dose of teplizumab IV for 14 days, repeated at Week 26

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV dosing daily for 14 days repeated at Week 26

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Teplizumab 33.3% Herold Regimen
Description: One third full dose of teplizumab IV for 14 days, repeated at Week 26

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Teplizumab Curtailed Herold Regimen
Description: Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
Study: NCT04008459

Intervention type: OTHER
Intervention: Therapeutic exercise class
Description: Physiotherapy exercise class includes education, stretching, strengthening, posture and balance interventions.
Study: NCT02010359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza 4 grams per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study: NCT02918968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral Capsule
Study: NCT04906304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandimmun (Neoral) dose plus cellcept
Description: Sandimmun (Neoral) dose plus cellcept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandimmun (Neoral) dose plus cellcept
Description: Sandimmun (Neoral) dose plus cellcept
Study: NCT03761901

Intervention type: DRUG
Intervention: 1L treatment
Description: chemotherapy, EGFR TKI, immunotherapy, other

Intervention type: DRUG
Intervention: 2L Treatment
Description: Chemotherapy, EGFR TKI, immunotherapy, other
Study: NCT02918968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Oral tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.
Study: NCT02103608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glide
Description: 6 facial hair reduction treatments with the Glide device, two weeks apart.
Study: NCT03761901

Intervention type: DRUG
Intervention: 3L treatment
Description: chemotherapy, EGFR TKI, immunotherapy, other
Study: NCT00994422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin cream
Description: Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle control
Description: Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
Study: NCT00762047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durasphere FI
Description: Durasphere Injection

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham injection with anesthesia
Study: NCT00722618

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written materials, telephone based education
Description: 4 new written materials, 15-20 minute educational session by telephone

Intervention type: OTHER
Group type: OTHER
Intervention: Written materials
Description: 2 written materials available on public website
Study: NCT04225117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion
Study: NCT02669212

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cardiopulmonary Exercise Test (CPET)
Description: All participants will undergo an exercise stress test

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cardiopulmonary Exercise Test (CPET)
Description: All participants will undergo an exercise stress test
Study: NCT02735343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compazine
Description: Compazine 10mg with diphenhydramine 25 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.3 mg/kg along with ondansetron 4 mg IV
Study: NCT00637416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg taken by mouth daily for 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo taken by mouth daily for 3 months
Study: NCT01661894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BrainPalTM
Description: Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
Study: NCT03778996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)
Description: Daily oral combination therapy for cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)
Description: Daily oral combination therapy for cancer
Study: NCT03549104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear Reduction Intervention
Description: FREE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: DSMES
Study: NCT01147055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
Study: NCT04225117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion
Study: NCT01147055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
Study: NCT04305171

Intervention type: PROCEDURE
Intervention: non-surgical periodontal treatment
Description: scaling and root planing, home care instruction

Intervention type: PROCEDURE
Intervention: non-surgical periodontal treatment
Description: scaling and root planing, home care instruction

Intervention type: PROCEDURE
Intervention: non-surgical periodontal treatment
Description: scaling and root planing, home care instruction

Intervention type: PROCEDURE
Intervention: non-surgical periodontal treatment
Description: scaling and root planing, home care instruction
Study: NCT01443702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapis Judaicus
Description: 2 g capsule per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 g capsule per day.
Study: NCT04225117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study: NCT04445454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: Bone marrow collection and MSC expansion cultures will be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of Liège as described in IMPD and its SOPs.
Study: NCT01575158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomipramine
Study: NCT01806675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fludeoxyglucose (18F-FDG)
Description: 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fludeoxyglucose (18F-FDG)
Description: 18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan
Study: NCT01575158

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo